The Valley Desk

NCT02965378 · Interventional trial

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Overall registry status Completed

Phase 2 · Phase 3

Conditions FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov